ESSA Pharma Inc
NASDAQ:EPIX

Watchlist Manager
ESSA Pharma Inc Logo
ESSA Pharma Inc
NASDAQ:EPIX
Watchlist
Price: 1.61 USD -1.23% Market Closed
Market Cap: 71.5m USD
Have any thoughts about
ESSA Pharma Inc?
Write Note

ESSA Pharma Inc
Cost of Revenue

Last Value
3-Years 3-Y CAGR
5-Years 5-Y CAGR
10-Years 10-Y CAGR
Quarterly
Annual
TTM
|

ESSA Pharma Inc
Cost of Revenue Peer Comparison

Competitors Analysis
Latest Figures & CAGR of Competitors

Company Cost of Revenue CAGR 3Y CAGR 5Y CAGR 10Y
ESSA Pharma Inc
NASDAQ:EPIX
Cost of Revenue
-$99.2k
CAGR 3-Years
-12%
CAGR 5-Years
-7%
CAGR 10-Years
N/A
B
Bright Minds Biosciences Inc
CNSX:DRUG
Cost of Revenue
N/A
CAGR 3-Years
N/A
CAGR 5-Years
N/A
CAGR 10-Years
N/A
Theratechnologies Inc
TSX:TH
Cost of Revenue
-$19.4m
CAGR 3-Years
7%
CAGR 5-Years
4%
CAGR 10-Years
-21%
Aurinia Pharmaceuticals Inc
NASDAQ:AUPH
Cost of Revenue
-$28.1m
CAGR 3-Years
-258%
CAGR 5-Years
N/A
CAGR 10-Years
-98%
Covalon Technologies Ltd
XTSX:COV
Cost of Revenue
-CA$12.7m
CAGR 3-Years
9%
CAGR 5-Years
-1%
CAGR 10-Years
-18%
Spectral Medical Inc
TSX:EDT
Cost of Revenue
-CA$1.2m
CAGR 3-Years
-22%
CAGR 5-Years
-14%
CAGR 10-Years
-5%
No Stocks Found

ESSA Pharma Inc
Glance View

Market Cap
71.5m USD
Industry
Biotechnology

ESSA Pharma, Inc. is a clinical stage pharmaceutical company. The company is headquartered in Vancouver, British Columbia and currently employs 30 full-time employees. The firm is focused on developing therapies for the treatment of prostate cancer. The Company’s lead candidate, EPI-7386 is an oral, small molecule that inhibits the androgen receptor (AR) through a novel mechanism of action (N-terminal domain inhibition). The firm is evaluating EPI-7386 as a monotherapy for the treatment of adult male patients with metastatic castration-resistant prostate cancer (mCRPC) resistant to standard-of-care treatments.

EPIX Intrinsic Value
8.86 USD
Undervaluation 82%
Intrinsic Value
Price

See Also

What is ESSA Pharma Inc's Cost of Revenue?
Cost of Revenue
-99.2k USD

Based on the financial report for Sep 30, 2024, ESSA Pharma Inc's Cost of Revenue amounts to -99.2k USD.

What is ESSA Pharma Inc's Cost of Revenue growth rate?
Cost of Revenue CAGR 5Y
-7%

Over the last year, the Cost of Revenue growth was -58%. The average annual Cost of Revenue growth rates for ESSA Pharma Inc have been -12% over the past three years , -7% over the past five years .

Back to Top